Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-κB pathways

Pigment Cell and Melanoma Research

Volumn 24, Issue 4, 2011, Pages 703-713

  Feng, Yongmei ^a   Barile, Elisa ^a   De, Surya K ^a   Stebbins, John L ^a   Cortez, Apple ^a   Aza Blanc, Pedro ^a   Villanueva, Jessie ^b   Heryln, Meenhard ^b   Krajewski, Stan ^a   Pellecchia, Maurizio ^a   Ronai, Ze'ev A ^a   Chiang, Gary G ^a  

^a BURNHAM INSTITUTE   (United States)

^b WISTAR INSTITUTE   (United States)

Author keywords

AKT; Melanoma; NF kB; Targeted therapy

Indexed keywords

2 [4 (2 DIMETHYLAMINOETHOXY)PHENYL] 4 (1 HYDROXYIMINO 5 INDANYL) 5 (4 PYRIDINYL) 1H IMIDAZOLE; ANTINEOPLASTIC AGENT; BI 69A11; I KAPPA B; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; SPHINGOSINE KINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DRUG INHIBITION; DRUG TARGETING; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MELANOMA; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADMINISTRATION, ORAL; ANIMALS; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; MELANOMA; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; NF-KAPPA B; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLONES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80051889138     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2011.00867.x     Document Type: Article

References (46)

1. Alessi, D.R., James, S.R., Downes, C.P., Holmes, A.B., Gaffney, P.R., Reese, C.B., and Cohen, P. (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol. 7, 261-269.
2. Alvarez, S.E., Harikumar, K.B., Hait, N.C. et al. (2010). Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 465, 1084-1088.
3. Bhaskar, P.T., and Hay, N. (2007). The two TORCs and Akt. Dev. Cell 12, 487-502.
4. Bhoumik, A., Gangi, L., and Ronai, Z. (2004). Inhibition of melanoma growth and metastasis by ATF2-derived peptides. Cancer Res. 64, 8222-8230.
5. Bollag, G., Hirth, P., Tsai, J. et al. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599.
6. Delhase, M., Li, N., and Karin, M. (2000). Kinase regulation in inflammatory response. Nature 406, 367-368.
7. Deveraux, Q.L., Roy, N., Stennicke, H.R., Van Arsdale, T., Zhou, Q., Srinivasula, S.M., Alnemri, E.S., Salvesen, G.S., and Reed, J.C. (1998). IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 17, 2215-2223.
8. Dhawan, P., and Richmond, A. (2002). A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J. Biol. Chem. 277, 7920-7928.
9. Dhawan, P., Singh, A.B., Ellis, D.L., and Richmond, A. (2002). Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res. 62, 7335-7342.
10. Easty, D.J., and Bennett, D.C. (2000). Protein tyrosine kinases in malignant melanoma. Melanoma Res. 10, 401-411.
11. Flaherty, K.T., Puzanov, I., Kim, K.B. et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
12. Forino, M., Jung, D., Easton, J.B., Houghton, P.J., and Pellecchia, M. (2005). Virtual docking approaches to protein kinase B inhibition. J. Med. Chem. 48, 2278-2281.
13. French, K.J., Upson, J.J., Keller, S.N., Zhuang, Y., Yun, J.K., and Smith, C.D. (2006). Antitumor activity of sphingosine kinase inhibitors. J. Pharmacol. Exp. Ther. 318, 596-603.
14. Gaitonde, S., De, S.K., Tcherpakov, M., Dewing, A., Yuan, H., Riel-Mehan, M., Krajewski, S., Robertson, G., Pellecchia, M., and Ronai, Z. (2009). BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma. Pigment Cell Melanoma Res. 22, 187-195.
15. Ghosh, S., and Karin, M. (2002). Missing pieces in the NF-kappaB puzzle. Cell 109(Suppl), S81-S96.
16. Gills, J.J., and Dennis, P.A. (2009). Perifosine: update on a novel Akt inhibitor. Curr. Oncol. Rep. 11, 102-110.
17. Govindarajan, B., Sligh, J.E., Vincent, B.J. et al. (2007). Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J. Clin. Invest. 117, 719-729.
18. Guttridge, D.C., Albanese, C., Reuther, J.Y., Pestell, R.G., and Baldwin Jr, A.S. (1999). NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 19, 5785-5799.
19. Hardwicke, M.A., Oleykowski, C.A., Plant, R. et al. (2009). GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol. Cancer Ther. 8, 1808-1817.
20. Hirai, H., Sootome, H., Nakatsuru, Y. et al. (2010). MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol. Cancer Ther. 9, 1956-1967.
21. Ivanov, V.N., Fodstad, O., and Ronai, Z. (2001). Expression of ring finger-deleted TRAF2 sensitizes metastatic melanoma cells to apoptosis via up-regulation of p38, TNFalpha and suppression of NF-kappaB activities. Oncogene 20, 2243-2253.
22. Johannessen, C.M., Boehm, J.S., Kim, S.Y. et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972.
23. Kapitonov, D., Allegood, J.C., Mitchell, C. et al. (2009). Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res. 69, 6915-6923.
24. Kosco, K.A., Cerignoli, F., Williams, S., Abraham, R.T., and Mustelin, T. (2008). SKAP55 modulates T cell antigen receptor-induced activation of the Ras-Erk-AP1 pathway by binding RasGRP1. Mol. Immunol. 45, 510-522.
25. Lee, J.T., Li, L., Brafford, P.A. et al. (2010). PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res. 23, 820-827.
26. Madhunapantula, S.V., and Robertson, G.P. (2009). The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res. 22, 400-419.
27. Micheau, O., Lens, S., Gaide, O., Alevizopoulos, K., and Tschopp, J. (2001). NF-kappaB signals induce the expression of c-FLIP. Mol. Cell. Biol. 21, 5299-5305.
28. Nazarian, R., Shi, H., Wang, Q. et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977.
29. Norris, J.L., and Baldwin Jr, A.S. (1999). Oncogenic Ras enhances NF-kappaB transcriptional activity through Raf-dependent and Raf-independent mitogen-activated protein kinase signaling pathways. J. Biol. Chem. 274, 13841-13846.
30. Ozes, O.N., Mayo, L.D., Gustin, J.A., Pfeffer, S.R., Pfeffer, L.M., and Donner, D.B. (1999). NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401, 82-85.
31. Paraiso, K.H., Fedorenko, I.V., Cantini, L.P., Munko, A.C., Hall, M., Sondak, V.K., Messina, J.L., Flaherty, K.T., and Smalley, K.S. (2010). Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br. J. Cancer 102, 1724-1730.
32. Paugh, S.W., Paugh, B.S., Rahmani, M. et al. (2008). A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood 112, 1382-1391.
33. Plas, D.R., and Thompson, C.B. (2005). Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24, 7435-7442.
34. Qi, J., Nakayama, K., Gaitonde, S., Goydos, J.S., Krajewski, S., Eroshkin, A., Bar-Sagi, D., Bowtell, D., and Ronai, Z. (2008). The ubiquitin ligase Siah2 regulates tumorigenesis and metastasis by HIF-dependent and -independent pathways. Proc. Natl. Acad. Sci. U S A 105, 16713-16718.
35. Ravi, R., Bedi, G.C., Engstrom, L.W., Zeng, Q., Mookerjee, B., Gelinas, C., Fuchs, E.J., and Bedi, A. (2001). Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat. Cell Biol. 3, 409-416.
36. Reinhardt, H.C., and Yaffe, M.B. (2009). Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr. Opin. Cell Biol. 21, 245-255.
37. Rhodes, N., Heerding, D.A., Duckett, D.R. et al. (2008). Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res. 68, 2366-2374.
38. Robertson, G.P. (2005). Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev. 24, 273-285.
39. Sarbassov, D.D., Guertin, D.A., Ali, S.M., and Sabatini, D.M. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101.
40. Sekulic, A., Haluska Jr, P., Miller, A.J. et al. (2008). Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin. Proc. 83, 825-846.
41. Shida, D., Takabe, K., Kapitonov, D., Milstien, S., and Spiegel, S. (2008). Targeting SphK1 as a new strategy against cancer. Curr. Drug Targets 9, 662-673.
42. Solit, D., and Rosen, N. (2010). Oncogenic RAF: a brief history of time. Pigment Cell Melanoma Res. 23, 760-762.
43. Ueda, Y., and Richmond, A. (2006). NF-kappaB activation in melanoma. Pigment Cell Res. 19, 112-124.
44. Villanueva, J., Vultur, A., Lee, J.T. et al. (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695.
45. Yang, J., and Richmond, A. (2001). Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res. 61, 4901-4909.
46. Yang, J., Splittgerber, R., Yull, F.E., Kantrow, S., Ayers, G.D., Karin, M., and Richmond, A. (2010). Conditional ablation of Ikkb inhibits melanoma tumor development in mice. J. Clin. Invest. 120, 2563-2574.